This MedLibrary.org supplementary page on Sanofi-aventis is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. (December 2007) |
 |
|
| Type | Public (Euronext SAN, NYSE, LSE and FWB) |
|---|---|
| Founded | August 20, 2004 by acquisition |
| Headquarters | Paris, France |
| Key people | Jean-François Dehecq Chairman Gérard Le Fur CEO |
| Industry | Pharmaceutical |
| Products | Lovenox®/Clexane® Thrombosis Plavix®/Iscover® Atherothrombosis |
| Revenue |  28 billion euros Consolidated net sales in (2007)($34.013 billion USD) |
| Employees | 100,000 (2007) |
| Website | en.sanofi-aventis.com |
Sanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company. The company is the world's fourth largest pharmaceutical company. Sanofi-Aventis engages in the research, development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but they also develop over-the-counter medication. Sanofi-Aventis cover 7 major therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines (with its subsidiary Sanofi Pasteur).
Sanofi-Aventis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[1]
Contents |
History
Sanofi Aventis
Sanofi Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of $54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.
Sanofi-Synthélabo
Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.
Connaught Campus
The Canadian operations of Sanofi-Aventis began as Connaught Laboratories/Connaught Medical Research Laboratories of the University of Toronto from 1914 to 1972. It was purchased by federal government's Canadian Development Corporation and later privatized. Sold to the French Institut Mérieux in 1989 and renamed Pasteur Merieux Connaught. A series of mergers would follow and the Canada unit was renamed Connaught Campus" of Aventis Pasteur. It is now the Canadian unit of Sanofi Pasteur and part of the Sanofi-Aventis empire.
Aventis
Aventis was formed in 1999 when Rhône-Poulenc S.A. merged with Hoechst Marion Roussel, which itself was formed from the merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.
Business
Management
Dehecq has been the General Manager of Sanofi since its creation in 1973.
Stockholders
Stockholders, Sanofi-aventis ownership structure as of February 29, 2008
- Breakdown of share ownership: 12.64% by Total, 8.65% by L'Oréal, 3.07% treasury shares, 1.24% employees, the remaining 70.40% are publicly traded.
- Voting rights distribution: 19.55% to Total, 14.72% to L'Oréal, 1.98% to employees, and 63.75% to the public.
Earnings
From Drugs.com
- 28 billion euros= Consolidated net sales 2007
- 4,537 M euros = R&D expenditure representing 16.2 % of net sales
- Nearly 100,000 employees
Aventis Foundation
The Aventis Foundation, a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation subsequent to the 1999 merger of Hoechst and Rhône-Poulenc. The foundation was responsible for sponsoring the Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, and which have grown to be one of the world's most prestigious non-fiction literary prizes. In 2006, the foundation severed its connection with the prizes and from 2007 they have been known as the Royal Society Prizes for Science Books and are managed by the Royal Society, the UK national academy of science.
Company profiles
Collaborative Research
In addition to internal research and development activities Sanofi-Aventis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[2][3] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[4]
References
- ^ "The Pharmaceutical Industry in Figures - 2008 Edition" (in english), European Federation of Pharmaceutical Industries and Associations (EFPIA), pp. 49. Retrieved on 2008-08-25.
- ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
- ^ "InnoMed PredTox Member Organizations". Retrieved on 2008-08-25.
- ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved on 2008-08-25.
External links
|
|||||
Wikipedia content modification information:
- This page was last modified on 3 October 2008, at 11:09.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Sanofi-aventis".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.